3-(2,2-dichloro-3-oxo-cyclobutyl)-propionic acid methyl ester | 1019842-07-9

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 3-(2,2-dichloro-3-oxo-cyclobutyl)-propionic acid methyl ester
• 英文别名: methyl 3-(2,2-dichloro-3-oxocyclobutyl)propanoate
• CAS: 1019842-07-9
• 化学式: C₈H₁₀Cl₂O₃
• 分子量: 225.072
• InChiKey: FBPJBSMABJJRPE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  13
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  43.4
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-(2,2-dichloro-3-oxo-cyclobutyl)-propionic acid methyl ester 在 溶剂黄146 、 锌 作用下， 反应 2.0h， 以58%的产率得到3-(3-oxo-cyclobutyl)-propionic acid methyl ester
  参考文献：
  名称：

  在基本条件下3取代的环丁酮的可控骨架重排†

  摘要：

  已经描述了在简单的基本条件下环丁酮的发散骨架重排。反应路径受3-取代环丁酮上Z基团的性质控制，导致形成各种内酯，内酰胺和酸。还报道了对映选择性反应的初步结果。

  DOI：

  10.1002/cjoc.201900510
• 作为产物：
  描述：

  4-戊烯酸甲酯 、 三氯乙酰氯 在 zinc/copper couple 、 三氯氧磷 作用下， 以 乙醚 为溶剂， 以74%的产率得到3-(2,2-dichloro-3-oxo-cyclobutyl)-propionic acid methyl ester
  参考文献：
  名称：

  在基本条件下3取代的环丁酮的可控骨架重排†

  摘要：

  已经描述了在简单的基本条件下环丁酮的发散骨架重排。反应路径受3-取代环丁酮上Z基团的性质控制，导致形成各种内酯，内酰胺和酸。还报道了对映选择性反应的初步结果。

  DOI：

  10.1002/cjoc.201900510

文献信息

• Substituted Purine And 7-Deazapurine Compounds
  申请人：Olhava Edward J.

  公开号：US20120142625A1

  公开（公告）日：2012-06-07

  The present invention relates to substituted purine and 7-deazapurine compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating disorders in which DOT1-mediated protein methylation plays a part, such as cancer and neurological disorders, by administering these compounds and pharmaceutical compositions to subjects in need thereof.

  本发明涉及取代嘌呤和7-脱氮嘌呤化合物。本发明还涉及包含这些化合物的药物组合物，以及通过向需要这些化合物和药物组合物的受试者施用这些化合物和药物组合物来治疗DOT1介导的蛋白质甲基化参与的疾病，例如癌症和神经系统疾病的方法。
• Substituted Purine and 7-Deazapurine Compounds
  申请人：Epizyme, Inc.

  公开号：US20140051654A1

  公开（公告）日：2014-02-20

  The present invention relates to substituted purine and 7-deazapurine compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating disorders in which DOT1-mediated protein methylation plays a part, such as cancer and neurological disorders, by administering these compounds and pharmaceutical compositions to subjects in need thereof.

  本发明涉及取代嘌呤和7-去氮嘌呤化合物。本发明还涉及含有这些化合物的药物组合物以及通过向需要这些化合物和药物组合物的受试者施用这些化合物和药物组合物来治疗DOT1介导的蛋白质甲基化参与的疾病，例如癌症和神经系统疾病的方法。
• SUBSTITUTED PURINE AND 7-DEAZAPURINE COMPOUNDS
  申请人：EPIZYME, INC.

  公开号：US20150366893A1

  公开（公告）日：2015-12-24

  The present invention relates to substituted purine and 7-deazapurine compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating disorders in which DOT1-mediated protein methylation plays a part, such as cancer and neurological disorders, by administering these compounds and pharmaceutical compositions to subjects in need thereof.

  本发明涉及取代嘌呤和7-脱氮嘌呤化合物。本发明还涉及含有这些化合物的制药组合物以及通过向需要这些化合物和制药组合物的受试者施用这些化合物和制药组合物来治疗DOT1介导的蛋白质甲基化参与的疾病，例如癌症和神经系统疾病的方法。
• Palladium-Catalyzed Diastereo- and Enantioselective Wagner−Meerwein Shift: Control of Absolute Stereochemistry in the C−C Bond Migration Event
  作者：Barry M. Trost、Jia Xie

  DOI：10.1021/ja7111299

  日期：2008.5.1

  Inducing absolute stereochemistry in Wagner-Meerwein shifts was examined in a ring expansion protocol. Initiated by generation of a pi-allylpalladium intermediate by hydropalladation of allenes, the ring expansion of allenylcyclobutanol substrates proceeded with excellent diastereo- and enantioselectivities. The results demonstrate that, during the C-C bond migration process, our chiral catalysts can control the stereochemistry of both the pi-allylpalladium intermediate and the corresponding migration bond. Moreover, the stereochemical outcome of the reaction can be rationalized very well with the working model of the chiral catalyst. The method provides an efficient way to synthesize highly substituted cyclopentanones with an alpha-chiral O-tertiary center which has various synthetic applications.
• SUBSTITUTED PURINE COMPOUNDS
  申请人：EPIZYME, INC.

  公开号：US20160368943A1

  公开（公告）日：2016-12-22

  The present invention relates to substituted purine compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating disorders in which DOT1-mediated protein methylation plays a part, such as cancer, by administering these compounds and pharmaceutical compositions to subjects in need thereof.